Jayastu Senapati

Hematology

1515 Holcombe Blvd
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Microclone with megaimpact.

Microclone with megaimpact.

Journal: Blood

Published: July 22, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

Journal: American journal of hematology

Published: May 14, 2026

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Journal: Haematologica

Published: May 04, 2026

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica

Published: April 22, 2026

Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage.

Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage.

Journal: Leukemia

Published: March 31, 2026

Short-chain fatty acid-producing microbes differentiate non-infectious and infectious neutropenic fever in leukemia.

Short-chain fatty acid-producing microbes differentiate non-infectious and infectious neutropenic fever in leukemia.

Journal: mSystems

Published: March 31, 2026

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Journal: Journal of hematology & oncology

Published: March 25, 2026

Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission.

Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission.

Journal: Haematologica

Published: March 23, 2026

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

Journal: American journal of hematology

Published: February 01, 2026

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Journal: Cancer

Published: January 28, 2026

Showing 1-12 of 90

Last Updated: 09/26/2026